Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults

Vaccine

Volumn 26, Issue 33, 2008, Pages 4160-4167

  Nolan, Terry M ^a   Richmond, Peter C ^b   Skeljo, Maryanne V ^c   Pearce, Georgina ^c   Hartel, Gunter ^c   Formica, Neil T ^c   Höschler, Katja ^d   Bennet, Jillian ^c   Ryan, David ^c   Papanaoum, Kelly ^e   Basser, Russell L ^c   Zambon, Maria C ^d  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c CSL LIMITED   (Australia)

^d UNIVERSITY COLLEGE DUBLIN   (Ireland)

^e ROYAL ADELAIDE HOSPITAL   (Australia)

Author keywords

Avian; Influenza; Pandemic; Prototype; Vaccine

Indexed keywords

ALUMINUM PHOSPHATE; AVIAN INFLUENZA VACCINE; HEMAGGLUTININ; THIOMERSAL;

ADULT; ARTICLE; AVIAN INFLUENZA; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS REACTION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECCHYMOSIS; FATIGUE; FEMALE; FEVER; FOLLOW UP; HEADACHE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA VIRUS A H5N1; INJECTION SITE EDEMA; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SPONTANEOUS ABORTION; SWEATING; TREATMENT OUTCOME; VOMITING;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; ALUM COMPOUNDS; ANTIBODIES, VIRAL; AUSTRALIA; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; IMMUNIZATION, SECONDARY; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; NEUTRALIZATION TESTS; VACCINES, INACTIVATED; VACCINES, SUBUNIT;

EID: 47349124848     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.05.077     Document Type: Article

References (17)

1. World Health Organisation. Cumulative number of confirmed human cases of avian influenza A (H5N1) reported to WHO; February 12, 2008. http://www.who.int/csr/disease/avian_influenza/country/en/(accessed February 14, 2008).
2. Committee for Proprietary Medicinal Products (CPMP). Guideline on dossier structure and content for pandemic influenza vaccine marketing authorisation application (CPMP/VEG/4717/03). London: European Agency for the Evaluation of Medicinal Products (EMEA); April 5, 2004.
3. Bresson J.L., Perronne C., Launay O., Gerdil C., Saville M., Wood J., et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 367 (2006) 1657-1664
4. Lin J., Zhang J., Dong X., Fang H., Chen J., Su N., et al. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet 368 (2006) 991-997
5. Treanor J.J., Campbell J.D., Zangwill K.M., Rowe T., and Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 354 (2006) 1343-1351
6. Leroux-Roels I., Borkowski A., Vanwolleghem T., Drame M., Clement F., Hons E., et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 370 (2007) 580-589
7. World Health Organisation. Antigenic and genetic characteristics of H5N1 viruses and candidate H5N1 vaccine viruses developed for potential use as pre-pandemic vaccines; March, 2007. http://www.who.int/csr/disease/avian_influenza/guidelines/summaryH520070 403.pdf (accessed October 18, 2007).
8. Nicolson C., Major D., Wood J.M., and Robertson J.S. Generation of influenza vaccine viruses on Vero cells by reverse genetics: an H5N1 candidate vaccine strain produced under a quality system. Vaccine 23 (2005) 2943-2952
9. Stephenson I., Wood J.M., Nicholson K.G., and Zambon M.C. Sialic acid receptor specificity on erythrocytes affects detection of antibody to avian influenza haemagglutinin. J Med Virol 70 (2003) 391-398
10. Stephenson I., Wood J.M., Nicholson K.G., Charlett A., and Zambon M.C. Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine. Virus Res 103 (2004) 91-95
11. Rowe T., Abernathy R.A., Hu-Primmer J., Thompson W.W., Lu X., Lim W., et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 37 (1999) 937-943
12. Committee for Proprietary Medicinal Products (CPMP). Note for guidance on harmonisation of requirements for influenza vaccines (CPMP/BWP/214/96). London: European Agency for the Evaluation of Medicinal Products (EMEA); March 12, 1997.
13. Nicholson K.G., Colegate A.E., Podda A., Stephenson I., Wood J., Ypma E., et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 357 (2001) 1937-1943
14. Treanor J.J., Wilkinson B.E., Masseoud F., Hu-Primmer J., Battaglia R., O'Brien D., et al. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 19 (2001) 1732-1737
15. Stephenson I., Bugarini R., Nicholson K.G., Podda A., Wood J.M., Zambon M.C., et al. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J Infect Dis 191 (2005) 1210-1215
16. Food and Drug Administration (FDA). Guidance for Industry. Clinical data needed to support the licensure of pandemic influenza vaccines. Rockville: US Department of Health and Human Services; May, 2007.
17. Potter C.W., and Oxford J.S. Determinants of immunity to influenza infection in man. Br Med Bull 35 (1979) 69-75